Various SGLT-2s have been shown to improve cardiovascular outcomes in the presence and absence of diabetes. A recent study evaluated the effect of dapagliflozin in mildly reduced or preserved ejection fraction. Join host, Geoff Wall, as he discusses how SGLT-2s may be a real GameChanger in heart failure with expert, Troy Lynn Lewis.
The GameChanger
The data showcasing the benefits of SGLT-2s in patients with heart failure with or without diabetes continues to grow. Dapagliflozin may be another treatment option for persons with heart failure.
Are you a CEimpact Member? Members get exclusive access to new courses and CE for this podcast. Over 62 hours of new CE each year + access to hundreds more on demand. Go to www.CEimpact.com to become a member today!
Show Segments
00:00 - Introductions
01:55 - The DELIVER Study
14:10 - GameChanger: DELIVER Discussion
20:44 - Connecting to Practice: Patient Considerations
26:11 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
Troy Lynn Lewis, PharmD, BC-ADM
Assistant Professor, Pharmacy Practice
Wilkes University
References and Resources
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Redeem your CPE or CME here
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the role of SGLT-2s in heart failure management
2. Discuss the results of the DELIVER trial
0.05 CEU/0.5 Hr
UAN: 0107-0000-22-414-H01-P
Initial release date: 11/14/2022
Expiration date: 11/14/2023
Additional CPE and CME details can be found here.